EUCTR2010-020454-34-AT进行中（未招募）1 期
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 1,700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Adults with documented evidence of multiple myeloma (per local assessment);
- •- Radiographic evidence of at least 1 bone lesion;
- •- Plan to receive or is receiving primary frontline anti-myeloma therapies;
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;
- •- Adequate organ function;
- •- Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 626
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1074
排除标准
- •- Nonsecretory multiple myeloma (unless baseline serum free light chain level is elevated);
- •- Plasma cell leukemia;
- •- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome;
- •- More than 30 days of previous treatment (before screening) with anti-myeloma therapy (does not include radiotherapy or a single short course of steroid [ie, less than or equal to the equivalent of dexamethasone 60 mg/day for 4 days]).
- •- Planned radiation therapy or surgery to bone (does not include procedures;
- •performed before randomization)
- •- Prior administration of denosumab;
- •- More than 1 previous dose of IV bisphosphonate administration;
- •- Use of oral bisphosphonates with a cumulative exposure of more than 1 year;
- •- Prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaTreatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myelomaMedDRA version: 8.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2006-000848-65-CZAmgen Inc1,690
进行中（未招募）
1 期
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2010-020454-34-PTAmgen Inc1,718
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaTreatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myelomaMedDRA version: 8.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2006-000848-65-DEAmgen Inc1,690
进行中（未招募）
不适用
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer SubjectsMedDRA version: 14.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2006-000339-93-DKAmgen Inc2,049
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate CancerTreatment of bone metastases in men with hormone- refractory prostate cancerMedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-000341-19-ITAmgen Inc1,700